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Abstract
Introduction Ionizing radiation is a known etiologic factor in tumorigenesis and its role in inducing malignancy in the treat-
ment of vestibular schwannoma has been debated. The purpose of this study was to identify a copy number aberration (CNA) 
profile or specific CNAs associated with radiation exposure which could either implicate an increased risk of malignancy 
or elucidate a mechanism of treatment resistance.
Methods 55 sporadic VS, including 18 treated with Gamma Knife Radiosurgery (GKRS), were subjected to DNA whole-
genome microarray and/or whole-exome sequencing. CNAs were called and statistical tests were performed to identify any 
association with radiation exposure. Hierarchical clustering was used to identify CNA profiles associated with radiation 
exposure.
Results A median of 7 (0–58) CNAs were identified across the 55 VS. Chromosome 22 aberration was the only recurrent 
event. A median aberrant cell fraction of 0.59 (0.25–0.94) was observed, indicating several genetic clones in VS. No CNA 
or CNA profile was associated with GKRS.
Conclusion GKRS is not associated with an increase in CNAs or alteration of the CNA profile in VS, lending support to its 
low risk. This also implies that there is no major issue with GKRS treatment failure being due to CNAs. In agreement with 
previous studies, chromosome 22 aberration is the only recurrent CNA. VS consist of several genetic clones, addressing the 
need for further studies on the composition of cells in this tumor.
Keywords Vestibular schwannoma · Gamma Knife Radiosurgery · Whole genome microarray · Intratumor genetic 
heterogeneity · Neurosurgery · Genetics
Introduction
Vestibular schwannoma (VS) is a benign intracranial neo-
plasm originating from the Schwann cells surrounding the 
vestibular portion of the 8th cranial nerve. VS makes up 
8% of intracranial tumors, with an annual incidence rate 
ranging from 10 to 22 per million [1, 2]. Although patients 
have a normal life expectancy, they experience significantly 
reduced quality of life attributable to dizziness, headache, 
hearing loss, facial nerve palsy and tinnitus [3]. Inactivation 
of the NF2 tumor suppressor gene is considered an initiating 
event in VS tumorigenesis, but it is likely that other factors 
also contribute [4, 5]. During recent years, several novel 
genetic events have been linked to the disease [6–8].
Gamma Knife Radiosurgery (GKRS) is a type of ion-
izing radiation therapy commonly used to treat VS. There 
are controversies regarding whether ionizing radiation might 
induce malignant degeneration or second neoplasms [9, 10]. 
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The risk for inducing neoplasms following ionizing radiation 
demonstrates a linear dose-response relationship, thus mak-
ing it theoretically feasible for GKRS inducing neoplasms in 
the normal tissue surrounding VS [11].
The aim of this study was to analyze the genome of 55 
sporadic VSs (sVS) to assess whether GKRS induce copy 
number aberrations (CNA). To understand the mechanism, 
we wanted to evaluate whether there are any genetic aberra-
tions associated with GKRS treatment resistance. Previous 
studies on structural changes in the VS genome have identi-
fied chromosome 22q loss as the only recurring event, pre-
sent in 25–83% of VSs [12]. However, previous studies have 
used techniques with lower resolution. Hence, our secondary 
aim was to characterize CNAs at a more detailed level as 
well as using this data to evaluate intratumor heterogeneity.
Materials and methods
Patient samples
VS tissue and matched blood sample was collected from 55 
patients without a history of NF2, who underwent first-time 
suboccipital resection of unilateral VS at the Department of 
Neurosurgery, Haukeland University Hospital, from August 
2003 to May 2017. Eighteen patients had been previously 
treated with GKRS for the same VS. Written informed con-
sent was received from all patients before tissue harvesting 
and the study was approved by the Regional Ethical Com-
mittee for medical research in Western Norway (2013/374). 
Tumor samples were harvested from the subcapsular part 
and snap frozen and stored in liquid nitrogen in the Bergen 
Neurosurgical Tissue Bank at Haukeland University Hos-
pital. All samples underwent routine histology. Volumetric 
tumor measurements were performed on BrainLab Elements 
if preoperative MRI scans were available (Version 2.4.0, 
BrainLab AG, Munich, Germany).
DNA extraction
DNA was extracted by disrupting the tumor tissue with the 
TissueLyser (Qiagen, Hilden, Germany) followed by pro-
tease treatment. DNA was then extracted using the QIAamp 
DNA Mini Kit (Qiagen). The DNA quality and quantity 
were evaluated with 1% SeaKem gel electrophoresis and 
NanoDrop (Thermo Fisher Scientific), respectively.
Whole‑genome DNA microarray
The CytoScan HD microarray (Affymetrix, UK) was 
used to detect chromosomal aberrations according to the 
manufacturer´s recommendations. CNAs were called using 
three different software: (1) chromosome analysis suite v3.2 
(ChAS, Affymetrix, UK), (2) Rawcopy [13] and (3) Nexus 
Copy Number (BioDiscovery, El Segundo, CA, USA). All 
data were mapped to the hg 19 reference genome build. 
We applied the following filtering criteria for including the 
called CNAs in downstream analysis: (1) marker count ≥ 90 
for gains; (2) marker count ≥ 30 for losses; (3) visual con-
firmation for mosaic variants; (4) segment size ≥ 1 Mbp for 
copy number neutral runs of homozygosity (CNN-ROH). 
Recurrent CNN-ROHs were further inspected for harboring 
small variants in whole-exome sequencing (WES) data using 
IGV[14]. BEDTools was used to produce a per sample union 
CNA call set, merge fragmented calls and to identify com-
mon regions harboring CNA across the cohort [15]. Can-
didate CNAs were manually inspected in IGV and filtered 
based on the following criteria: (1) variant not present in 
databases of copy number variants (CNV) in normal healthy 
controls (Affymetrix reference database with n = 2691, Data-
base of genomic variants as per May 2016 [16]); (2) variant 
containing NCBI reference sequence gene; (3) variant pre-
sent in 3 or more samples. GISTIC [17] was used to identify 
statistically significant aberrated regions across the cohort.
For estimating aberrant cell fraction and allele specific 
copy number profiles in the tumors, the Allele-Specific Copy 
number Analysis of Tumors 2.5.2 (ASCAT) software was 
used [18]. Per sample log ratio (LR) and B-allele frequency 
(BAF) values from the 27 tumors analyzed with Rawcopy 
was used for input. ASCAT was run with default parameters 
except from gamma which was set to 0.45 in compliance 
with the estimated compression factor in the Affymetrix 
CytoScan HD microarray.
Whole‑exome sequencing (WES)
WES data were available from a previous study on 46 
sVSs, including 18 samples also analyzed with microar-
ray [7]. The Sequenza software version 2.1.2 was used for 
estimating aberrant cell fraction and calling allele-specific 
copy number profiles from the BAM files [19]. The 18 sam-
ples analyzed with both microarray and WES were used as 
training data to set the following parameters for running 
Sequenza: gamma = 100, kmin = 30 and median normaliza-
tion method. Aberrant cell fraction estimates below 0.20 
were not included as the software was not trained to estimate 
at this level.
Statistical analyses
Statistical analyses, including descriptive statistics, con-
tingency table statistics, Mann-Whitney U test and linear 
correlation, were done using Nexus Copy Number and/or 
R [20]. Clustering of the sample set based on CNA profiles 
was done with Rawcopy using the hclust R package as well 
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as with the built-in complete linkage hierarchical clustering 
algorithm in Nexus Copy Number.
Results
Patient characteristics
55 patients presenting with sVS were included (Table 1). 
Mean age at the time of surgery was 53.3 years ranging 
from 18 to 80 years. Mean preoperative tumor volume was 
8.4 cm3 ranging from 0.37 to 26.78 cm3. 18 patients under-
went Gamma Knife Radiosurgery (GKRS) prior to surgical 
removal of the primary tumor. Mean time between GKRS 
and surgery was 1429 days ranging from 280 to 3478 days, 
and the margin dose in all cases was 12 Gy. All but three 
GKRS treated patients needed surgical removal because of 
post-treatment growth; VS14 experienced dizziness, VS16 
acquired an intratumoral cyst and VS26 developed trigemi-
nal neuralgia. Five patients had cystic tumors.
Chromosome 22 aberration is the only recurrent 
copy number aberration in sVS
Using the union call set from filtered ChAS and Rawcopy 
segments, a median of 7 (0–58) CNAs per sample was iden-
tified. Figure 1 illustrates the karyogram of a representative 
sVS. A median of 0.17% of the sVS autosome was affected 
by CNA. 38 genomic loci were found to harbor a CNA in 
three or more samples. However, all but the chromosome 
22 loss were common variants (CNV) present in healthy 
controls. A median of 3 (0–134) CNN-ROHs were seen in 
the tumors. None of the recurrent regions across the sam-
ples harbored any point mutations or indels. ASCAT was 
then used to infer aberrant cell fraction and absolute allele 
specific copy number. The number of CNAs identified by 
the different approaches were highly correlated (r = 0.831, 
p < 0.001). ASCAT identified a median of 21 (2–219) 
autosomal CNAs with a median gain-to-loss ratio of 1.25 
(0.25–6.50). The only recurrent CNA retained after filtering 
was chromosome 22 loss or CNN-ROH. GISTIC analyses 
on segmented data from Rawcopy and Nexus Copy Num-
ber identified chromosome 22 loss as a significantly recur-
rent event (Q-bound = 1.36 × 10− 9, G-score = 15.72). Other 
events identified were either CNVs or non-coding DNA. 
Neither tumor volume, volumetric growth nor age was sig-
nificantly associated with chromosome 22 status, number 
of CNAs or aberrant cell fraction. Aggregating the results 
from ASCAT and Sequenza, 25 out of 55 (45%) tumors har-
bored a chromosomal aberration at chromosome 22 includ-
ing seven tumors with CNN-ROH, 17 tumors with loss and 
one tumor with a loss followed by a CNN-ROH (Table 2). 
Most aberrations encompassed all the analyzed probes on 
the chromosome suggesting a total loss of the chromosome. 
The chromosome 22 aberrated group was comparable to the 
entire cohort with regards to sex distribution, GKRS expo-
sure, age, tumor volume and time elapsed from GKRS to 
surgery. Combining the structural variants identified in this 
study with whole-exome sequencing and multiplex ligation-
dependent amplification (MLPA) data from our previous 
study, 41 out of 55 (75%) harbored at least one NF2 mutation 
[7]. When only including the samples that were analyzed 
with whole-exome sequencing, 38 out of 46 (83%) harbored 
at least one mutation including 13 samples with one hit and 
25 samples with 2 hits.
Mosaic chromosome 22 loss reveals intratumor 
genetic heterogeneity in sVS
Among the chromosome 22 aberrated tumors, a median 
aberrant cell fraction of 0.59 (0.25–0.94) was observed 
(Table 2). Aberrant cell fraction did not correlate with 
tumor growth. The level of mosaicism is demonstrated in 
the splitting of the BAF signal (Fig. 2). A Chi-square test 
demonstrated that tumors with aberrated chromosome 22 
were significantly more likely to be estimated as heterogene-
ous (χ2 = 22.212, Fisher’s p = 0.000). Among the four tumors 
with diploid chromosome 22 and estimated aberrant cell 
fraction below 1, one tumor had several CNN-ROHs, one 
tumor harbored another large CNA [del [21] (q11.2q22.3)], 
whereas the two other tumors were estimated to have an 
aberrant cell fraction between 0.95 and 1. It seems likely 
that ASCAT and Sequenza are dependent on a large CNA to 
estimate aberrant cell fraction and hence only estimates from 
chromosome 22 aberrant tumors were included for report-
ing (Table 2). In four chromosome 22 aberrated tumors, an 
aberrant cell fraction could not be estimated, and all these 
tumors had WES data only.
Among the 46 tumors analyzed with WES, a total of 
45 small nucleotide variants and indels were found with a 
median variant allele frequency of 24% [7]. We found a posi-
tive correlation between the estimated aberrant cell fraction 
from the chromosome 22 aberrated tumors and variant allele 
frequency (adj  R2 = 0.43, p = 0.006).
GKRS does not alter the copy number profile of sVS
A Chi-square test of independence demonstrated no dif-
ference in the frequency of chromosome 22 aberration 
in irradiated (39%) and radiation-naïve (49%) tumors 
(χ2 = 0.155, Fisher’s p = 0.572). We found no differences 
in aberrant cell fraction, number of CNAs, type of CNA 
or the portion of the genome covered by CNAs between 
the irradiated and radiation-naïve tumors. The clustering 
algorithms applied demonstrated that clusters identified 
did not rely on previous radiation exposure (Fig. 3). Using 
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Table 1  Patient demographics. 
Patient demographics of 55 
vestibular schwannomas
ID GKRS1 Age Volume2 Sex Microarray3 WES4
VS1 na 58 4.25 F X X
VS2 na 61 NA M X X
VS3 na 68 16.34 M X X
VS4 na 67 3.17 F X X
VS5 na 58 12.82 M X X
VS6 na 57 NA F X X
VS7 na 62 6.46 F X X
VS8 na 54 3.34 F X X
VS9 na 75 17.71 F X X
VS10 699 50 NA F X X
VS11 1028 61 NA M X X
VS12 3478 58 NA M X X
VS13 1084 66 NA M X X
VS14 2170 28 1.20 F X X
VS15 1079 64 NA M X X
VS16 574 66 11.46 M X X
VS17 560 53 1.46 F X X
VS18 2371 69 1.67 F X X
VS19 1499 61 0.12 M X
VS20 280 44 0.62 M X
VS21 1476 66 3.50 M X
VS22 2968 80 0.41 M X
VS23 1987 60 0.47 M X
VS24 720 72 1.03 F X
VS25 811 68 0.14 M X
VS26 1646 61 4.56 F X
VS27 1288 61 2.52 M X
VS29 na 64 11.39 F X
VS30 na 39 11.99 F X
VS31 na 40 8.77 F X
VS33 na 59 7.11 M X
VS34 na 33 6.89 M X
VS35 na 30 15.05 M X
VS36 na 45 5.41 F X
VS37 na 48 4.29 M X
VS38 na 18 16.61 F X
VS39 na 58 9.70 F X
VS40 na 42 9.39 M X
VS41 na 25 12.18 F X
VS42 na 45 18.42 F X
VS43 na 36 18.01 F X
VS44 na 58 7.87 F X
VS45 na 60 26.77 F X
VS46 na 33 11.68 M X
VS48 na 42 5.46 M X
VS49 na 54 18.21 M X
VS50 na 63 3.20 M X
VS51 na 47 NA M X
VS52 na 55 6.80 M X
VS53 na 66 8.57 M X
VS54 na 37 12.94 F X
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the Nexus Copy Number built-in comparison analysis, we 
did not identify any CNA or gene associated with radiation 
exposure. We sought specifically for CNAs affecting genes 
coding for enzymes annotated to function in DNA repair 
pathways. Using the union call set, four tumors (two irra-
diated and two radiation-naïve) harbored CNAs affecting 
DNA repair genes. No difference between the groups was 
seen  (x2 = 0.04, p = 0.58). The results were similar for the 
ASCAT call set.
Table 1  (continued) ID GKRS1 Age Volume2 Sex Microarray3 WES4
VS55 na 26 10.40 F X
VS56 na 57 10.66 M X
VS57 na 63 6.73 M X
VS58 na 42 5.01 F X
1 Time in days between Gamma Knife Radiosurgery and microsurgery
2 Tumor volume in  cm3
3 Samples with DNA microarray data marked with X
4 Samples with WES data marked with X
Fig. 1  Karyogram for sample VS10. Circos plot of copy number and 
single nucleotide polymorphism probe data for sample VS10, cre-
ated using the Circos software [37]. The tracks from outside inwards: 
chromosome numbers, chromosomal position in Mb, copy number 
and allele patterns. Copy number gains and losses are highlighted 
in blue and red, respectively. Most chromosomes show a continuous 
disomic copy number profile with a normal three band allele pattern 
(allele configurations AA, AB and BB). On chromosome 22, high-
lighted in the middle, we see an allelic loss (allele configuration A0 
and B0) in the region of NF2 followed by a CNN-ROH (allele con-
figuration AA and BB). However, the aberrations are only present in 
63% of the cells giving rise to the split in the middle line of the allele 
pattern
Table 2  Chromosome 22 aberrations 
Chromosome 22 aberrations identified in VS. The naming of the 
aberrations starts with chromosome number followed by band, loca-
tion in bp and type of aberration (x1 for hemizygous loss and hmz for 
copy number neutral run of homozygosity). The last column gives the 
fraction of cells harboring the aberration
ID Aberration Aberrant 
cell frac-
tion
VS1 22q11.1q13.33(16052530–51244019) × 1 0.86
VS8 22q11.1q13.33(16052530–51244019) × 1 0.46
VS9 22q11.1q13.33(17922735–51244019) hmz 0.46
VS10 22q11.1q13.33(19639383–37988033) × 1 
22q11.1q13.1(37988034–51244019) hmz
0.63
VS13 22q11.1q13.33(16052530–51244019) × 1 0.61
VS16 22q11.1q13.33(16052530–51244019) × 1 0.46
VS17 22q11.1q13.33(16052530–51244019) × 1 0.29
VS20 22q11.1q13.33(16052530–51244019) × 1 0.26
VS22 22q11.1q13.33(16052530–51244019) × 1 0.45
VS27 22q11.21q13.33(18581773–51244019) hmz 0.25
VS33 22q11.1q13.33(16157603–51220938) × 1 0.63
VS34 22q11.1q13.33(16157940–51237063) × 1 0.59
VS37 22q11.1q13.33(16157827–51220938) hmz 0.36
VS38 22q11.23q12.3(24167473–33156768) hmz NA
VS42 22q11.1q13.33(16157762–51220938) × 1 0.27
VS43 22q11.1q13.33(20761063–51220938) × 1 0.94
VS45 22q11.1q13.33(16157623–51237063) × 1 0.79
VS46 22q11.22q13.33(22313733–51237063) hmz NA
VS50 22q11.1q13.33(16157622–51237063) × 1 0.77
VS51 22q11.1q13.33(16157603–51219006) × 1 0.66
VS53 22q11.1q13.33(26688838–51237063) × 1 0.8
VS54 22q11.1q13.33(16157603–51237063) × 1 NA
VS55 22q11.1q13.33(16157771–51220938) hmz NA
VS57 22q11.23q13.33(23523234–51220938) hmz 0.4
VS58 22q11.1q13.33(16269779–51216564) × 1 0.84
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Discussion
GKRS has become increasingly popular in treating VS 
over the past decades [21]. Several case reports have 
questioned its safety regarding malignant degeneration of 
benign tumors and inducing new neoplasms. For a review, 
see [9]. A dominating theory explaining the relationship 
between ionizing radiation dose and harmful effects is 
called the “linear no-threshold model” [22]. Although 
disputed, this theory explains that there is no safe limit, 
and that even a small amount of radiation might damage 
the DNA and initiate tumorigenesis. Standard treatment 
protocol with GKRS delivers 12 Gy to the periphery with 
a sharp decrease in the amount of energy delivered to the 
surrounding tissue. In the focus of the radiation, the dos-
age will be enough to initiate necrosis. In the periphery, 
we hypothesize that the dosage will harm the DNA and 
lead to one of the following: (1) detrimental DNA damage 
leading to apoptosis, (2) DNA mutations with tumorigenic 
potential, (3) DNA mutations with other or no effect at 
all. Although it seems theoretically feasible for GKRS to 
increase the risk of malignancy, epidemiologic studies do 
not support this [10, 23].
Previous studies have reported different genetic findings 
associated with radiation in VS. Lee et al. analyzed 30 sVS, 
including 4 irradiated tumors, utilizing microsatellite analy-
sis to find that chromosome 22 aberration was more com-
mon in the radiation-naïve tumors [24]. Warren et al. found, 
using comparative genomic hybridization, that among 10 
neurofibromatosis type 2 patients, radiation was associated 
with chromosomal aberrations [25]. In a recent study, Aaron 
et al. used WES on 12 VS, including two irradiated, to con-
clude that irradiated VS have increased copy number events 
and mutational burden [26]. One irradiated tumor harbored 
184 mutations whereas the average across the cohort was 
18.5. However, in our previous study utilizing WES on 46 
VS, including 8 irradiated tumors, we also demonstrated 
one outlier, but this was radiation-naïve [7]. Taken together, 
this weakens the association between radiation exposure and 
hypermutated tumors.
This is the largest study investigating the effect of GKRS 
on the sVS genome. Using hierarchical clustering of the 
Fig. 2  Vestibular schwannoma consist of more than one major 
genetic clone. Circos plot of copy number and single nucleotide 
polymorphism probes in chromosome 22 for four vestibular schwan-
nomas with increasing aberrant cell fraction. The tracks from out-
side inwards: chromosomal position in Mb on chromosome 22, copy 
number and allele patterns respectively for four vestibular schwanno-
mas with increasing aberrant cell fraction. All samples demonstrate 
hemizygous loss of chromosome 22. The outermost sample shows a 
minor drop in copy number and a barely visible split in the middle 
line in the allele pattern because only 26% of the cells are aberrated. 
Moving inwards, the copy number drops and the split in the allele 
pattern increases, demonstrating an increase in aberrant cell fraction
Fig. 3  GKRS treatment does 
not affect the genomic CNA 
profile of vestibular schwan-
noma. Dendrogram of hierarchi-
cal clustering of the autosomal 
CNA patterns of vestibular 
schwannomas. Irradiated and 
radiation-naïve tumors depicted 
as red and black terminal 
vertical lines respectively. The 
clusters are not associated with 
previous radiation exposure
Irradiated tumors
Radiation - naïve tumors
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genome-wide CNA profiles, we did not identify any clus-
tering based on radiation exposure. Neither did we find any 
gene or genomic loci that correlated with radiation exposure. 
The discrepancy with previous studies on the subject might 
be due to larger sample size and the method used. In a recent 
paper, 18 radiation-induced meningiomas were analyzed 
for tumor-specific CNAs [27]. A mean total of 22% of the 
exome was affected by CNA. This is in stark contrast with 
our irradiated tumors exhibiting a median of 0.14% of the 
autosome covered by CNA. The meningioma patients had 
received cranial radiotherapy for diseases like medulloblas-
toma and central nervous system lymphoma, a therapy that 
delivers higher radiation doses to healthy tissue compared to 
GKRS. This comparison lends support to the fact that GKRS 
does not induce collateral damage to the extent seen after 
conventional radiotherapy. We expect that GKRS causes 
mutations in the normal tissue surrounding VS. However, 
the mutations induced need to provide a selective growth 
advantage to the affected cell initiating a clonal expansion 
for it to be detected using bulk DNA analysis and even for it 
to be clinically relevant. It is feasible that a growth advan-
tage might be obtained, but that it is very rare in agreement 
with epidemiologic studies and our study.
Between 5 and 10% of sVSs do not respond to GKRS 
treatment. The GKRS response might depend on both treat-
ment and tumor factors. Studying the tumor factors might 
elucidate the mechanism of radioresistance as well as iden-
tify biomarkers. Archibald et al. found a higher expression 
of the immune-related protein B7-H1 among irradiated sVS, 
but no difference at RNA level [28]. This might be a con-
sequence of the radiation induced inflammation and hence 
not connected to the cause of the radioresistance. Through 
the use of genome-wide association studies, gene expression 
and DNA sequencing, several biomarkers of radiotherapy 
treatment response have been found in neoplasms [29–32]. It 
has been postulated that enhanced DNA repair mechanisms 
lead to radiotherapy treatment failure. Hence, we sought to 
evaluate whether the radioresistant VSs harbored CNAs in 
DNA repair genes. Although we identified some impaired 
DNA repair genes, they were distributed equally among the 
irradiated and radiation-naïve tumors. We did not find any 
other gene or genomic loci associated with radioresistance. 
One pitfall of our study is that we do not have positive con-
trols for tumors that respond to GKRS treatment as these 
are not surgically removed. However, as GKRS treatment is 
effective in 90–95% of sVSs, we believe that the radiation-
naïve tumors included in this study serve as a viable sur-
rogate for GKRS treatment responders. Also, to detect any 
genetic aberrations caused by ionizing radiation, a longitu-
dinal study design using paired samples of radiation-naïve 
and irradiated tumors would be the most sensitive. However, 
we believe our study design would be able to detect any large 
effects ionizing radiation.
Among the chromosome 22 aberrated tumors, a median 
of 59% of the cells harbored the CNA, suggesting that VS 
consists of more than one major clone. This is in accord-
ance with our previous study on small mutations, where we 
reported a median NF2 variant allele frequency of 24% [7]. 
Considering the bias of ASCAT only calling heterogene-
ity in tumors with large aberration and the variant allele 
frequencies reported in our WES study, it seems likely that 
most or all VSs consists of more than one major genetic 
clone. A recent study by Lewis et al. found that tumor-asso-
ciated macrophages constituted 50–60% of the cells in eight 
growing VSs [33]. Hence, infiltrating macrophages might 
constitute the clone coexisting with the neoplastic cells. 
Further on, Lewis et al. found that macrophages accounted 
for the proliferating cells in VS. However, we did not find 
any association between aberrant cell fraction, which might 
correlate inversely with the macrophage fraction, and tumor 
growth. The finding of intratumor genetic heterogeneity has 
significant implications for molecular studies on VS. We saw 
from our data that the lower the aberrant cell fraction, the 
higher the number of CNAs called. This implies a problem 
with the software and theoretic framework underlying call-
ing of aberrations. The possibly large fraction of infiltrating 
macrophages would also preclude other molecular studies 
using bulk analyzing, like transcriptome and proteome stud-
ies. A possible way to bypass this could be to apply single-
cell analysis to provide a better understanding VS molecular 
biology.
Carlson et al. recently profiled structural variants in sVS 
using whole-genome sequencing to find biallelic inactivation 
of the NF2 gene in all 22 sVSs analyzed [8]. Previous stud-
ies have demonstrated NF2 variants in 15–84% of the ana-
lyzed tumors [34]. Combining our data from whole-genome 
microarray, WES and MLPA, we found at least one variant 
in NF2 in 83% of the tumors. This discrepancy might reflect 
differences in the detection limit of the methods used or vari-
ations in the study population. Carlson et al. also found that 
VSs with severe phenotype tended to harbor large structural 
variants outside chromosome 22. However, we did not find 
any association with specific CNAs and previous radiation 
exposure, tumor size or age. In agreement with Carlson et al. 
we did not find any recurrent focal alterations and it seems 
unlikely that this kind of genetic event plays a significant 
role in VS tumorigenesis [8]. Previous studies have identi-
fied recurrent non-chromosome 22 regions affected by CNA, 
like 9q34, 17q, 19, 16q and 9p21 [25, 35]. We found a total 
of 38 genomic loci affected in three or more tumors. How-
ever, all but chromosome 22 aberration were normal variants 
present in healthy subjects.
In our previous study, we analyzed a total of 46 VS, 
including 8 irradiated VS, with WES and MLPA to con-
clude that radiation exposure or radiosensitivity is not asso-
ciated with increased mutational burden or specific small 
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mutations [7]. Ionizing radiation is known to induce DNA 
double-strand breakage resulting in CNA [36]. To address 
this issue, we analyzed an extended set of irradiated sam-
ples with whole-genome DNA microarray to conclude that 
neither specific CNAs, nor the genomic CNA profile play a 
role either. The methods used in these studies are not capable 
of detecting structural variants not affecting gene dosage or 
heterozygosity (e.g. inversions and translocations). Hence, 
future studies should address this as well as epigenetic 
mechanisms to elucidate the molecular consequences of ion-
izing radiation in VS as well as markers of radioresistance.
Conclusions
We did not find any CNA or genomic CNA profile associated 
with radiation exposure in VS. This finding lends support 
to the low risk of GKRS. We demonstrated that VS exhibit 
intratumor heterogeneity and further studies are warranted 
to elucidate whether it is different tumor clones or normal 
cell infiltration. In our study, the only recurrent CNA in VS 
is hemizygous loss or copy number neutral loss of heterozy-
gosity on chromosome 22.
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